ERBB2 and metastatic malignant neoplasm in the lymph nodes: Shorter DFS rates were related to younger age (<62 years; P = 0.003), larger tumor size (≥3 cm; p<0.001), solid predominant type tumors (P = 0.011), micropapillary predominant type tumors (P = 0.007), pleural invasion (P = 0.001), lymphovascular invasion (P<0.001), lymph node metastasis (P<0.001), advanced pTNM stage (P<0.001), HER2 protein overexpression (H-score ≥200; P = 0.034), and HER2 high-level amplification (P = 0.003).